Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Logothetis Discusses Prostate Cancer Therapy

January 11th 2012

Dr. Christopher Logothetis, from the MD Anderson Cancer Center, Discusses Prostate Cancer Therapy

Dr. Gomella Discusses Androgen-Deprivation Therapy

January 9th 2012

Dr. Leonard Gomella, from Kimmel Cancer Center, Discusses Androgen-Deprivation Therapy

Hypofractionated Radiation Trial Results Comparable to Standard in Intermediate - and High-Risk Patients

January 9th 2012

Delivering higher doses of external beam radiation in a shorter period of time was as effective as conventional radiation in preventing treatment failure in men with intermediate- to high-risk prostate cancer.

Radium-223 Properties Conducive to mCRPC Care

December 30th 2011

Radium-223, an alpha-emitting radiopharmaceutical, has been shown to improve overall survival (OS) in men with metastatic castrationresistant prostate cancer (mCRPC) in an interim analysis of the ALSYMPCA trial.

Statins linked to lower risk of prostate cancer mortality in middle-aged men

December 30th 2011

Middle-aged men taking a class of drugs called statins to reduce cholesterol levels were shown to have reduced the risk of mortality due to prostate cancer by approximately 50%, according to a new study...

Dr. Sartor on Patients in the ALSYMPCA Radium-223 Trial

December 20th 2011

Dr. Oliver Sartor, from Tulane Cancer Center, Describes Patients in the ALSYMPCA Radium-223 Trial

Men Undergoing Prostate Biopsy Have Higher Hospitalization Rates

December 20th 2011

The rate of hospitalization in older men within 30 days of a prostate biopsy is more than double that occurring in a control population not undergoing a biopsy.

Ibandronate and Radiotherapy Provide Equivalent Pain Relief in Metastatic Prostate Cancer That Has Metastasized to the Bone

December 16th 2011

A single dose of radiotherapy and a single injection of ibandronate provided similar pain relief from bone metastases in men with metastatic prostate cancer.

Castration-Resistant Prostate Cancer: A Conversation With Cora N. Sternberg, MD

December 16th 2011

Physicians and patients with castration-resistant prostate cancer (CRPC) have an increasing number of treatment options that improve outcomes.

Early Alopecia May Be Linked to Prostate Cancer

December 12th 2011

New data support a potential link between early-onset androgenic alopecia and the development of prostate cancer.

Prostate Cancer Test Deemed Unnecessary by Government Panel

December 8th 2011

After decades of use, a routine test used for diagnosing prostate cancer has come under fire after a government panel questioned its safety.

Dr. Alter Discusses Provenge MOA and Tolerability

December 2nd 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability

Dr. Petrylak on Sequencing Prostate Cancer Therapies

December 1st 2011

Dr. Daniel Petrylak from Herbert Irving Comprehensive Cancer Center Discusses Sequencing Prostate Cancer Therapies

Recent Advances Put Focus on Tumor Microenvironment

November 30th 2011

The impact that the tumor microenvironment has on the survival and growth of cancer cells is becoming increasingly well defined on several fronts.

Dr. Sartor Discusses Prostate Cancer Drug Combinations

November 29th 2011

Dr. Oliver Sartor from Tulane Cancer Center Discusses Prostate Cancer Drug Combinations

Dr. Alter Discusses the Provenge Treatment Process

November 17th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process

Dr. Sartor Discusses the Novel Agent Radium-223

November 15th 2011

Dr. Oliver Sartor from Tulane Cancer Center Discusses the Novel Agent Radium-223

Dr. Alter Discusses the Immunotherapy Provenge

November 11th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Denosumab Delays Onset of Metastases in Castration-Resistant Prostate Cancer

October 18th 2011

Inhibiting the RANKL protein, which is involved in bone metabolism, can delay the onset of the bone metastases in men with castration-resistant prostate cancer.

Changing Fate of Bone-Related Therapies for Prostate Cancer

October 18th 2011

Two trials are underway that not only address bone-related issues but might improve survival rates for patients.